Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul-Aug;20(4):293-8.
doi: 10.5152/dir.2014.13319.

Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up

Affiliations

Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up

Soroush Rais-Bahrami et al. Diagn Interv Radiol. 2014 Jul-Aug.

Abstract

Purpose: We aimed to determine the natural history of small index lesions identified on multiparametric-magnetic resonance imaging (MP-MRI) of the prostate by evaluating lesion-specific pathology and growth on serial MP-MRI.

Materials and methods: We performed a retrospective review of 153 patients who underwent a minimum of two MP-MRI sessions, on an institutional review board-approved protocol. Index lesion is defined as the lesion(s) with the highest cancer suspicion score based on initial MP-MRI of a patient, irrespective of size. Two study cohorts were identified: (1) patients with no index lesion or index lesion(s) ≤7 mm and (2) a subset with no index lesion or index lesion(s) ≤5 mm. Pathological analysis of the index lesions was performed following magnetic resonance/ultrasound fusion-guided biopsy. Growth rate of the lesions was calculated based on MP-MRI follow-up.

Results: Patients with small index lesions measuring ≤7 mm (n=42) or a subset with lesions ≤5 mm (n=20) demonstrated either benign findings (86.2% and 87.5%, respectively) or low grade Gleason 6 prostate cancer (13.8% and 12.5%, respectively) on lesion-specific targeted biopsies. These lesions demonstrated no significant change in size (P = 0.93 and P = 0.36) over a mean imaging period of 2.31±1.56 years and 2.40±1.77 years for ≤7 mm and ≤5 mm index lesion thresholds, respectively. These findings held true on subset analyses of patients who had a minimum of two-year interval follow-up with MP-MRI.

Conclusion: Small index lesions of the prostate are pathologically benign lesions or occasionally low-grade cancers. Slow growth rate of these small index lesions on serial MP-MRI suggests a surveillance interval of at least two years without significant change.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient selection for analysis cohorts of small index lesions found on initial multiparametric MRI (MP-MRI).
Figure 2.
Figure 2.
Lesion-based multiparametric MRI cancer suspicion scoring system. T2W MRI, T2-weighted MRI; ADC, apparent diffusion coefficient; DCE MRI, dynamic contrast enhanced MRI; DW-MRI, diffusion-weighted MRI; MP-MRI, multiparametric MRI.
Figure 3. a–d.
Figure 3. a–d.
Patient MRI depicting baseline T2-weighted (a) and diffusion-weighted imaging (DWI) (b) sequences which identified a right midanterior peripheral zone lesion measuring 5 mm (arrows). Subsequent T2-weighted (c) and DWI (d) sequences show no change in size or characteristics (arrows). At both time points, dynamic contrast-enhanced MRI and MR spectroscopy were negative in this area, maintaining a moderate level of suspicion. Gleason 3+3=6 was diagnosed in <5% of targeted biopsy cores.

Similar articles

Cited by

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
    1. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101:894–904. - PubMed
    1. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175–181. - PMC - PubMed
    1. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71:933–938. - PubMed
    1. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368–374. - PubMed

Publication types